Eli Lily and Investor Group Form BioCritica
Eli Lily and an investor group have formed BioCritica, a Central Indiana-based biotech that will focus on the U.S. development and commercialization of Xigris. Financial terms were not announced. Care Capital and NovaQuest Capital are part of the investor group. Xigris is Lilly's medicine to treat sepsis.
23 May 2011•8 mins read
